Prescrire Int. 2010 Aug;19(108):186-8.
In November 2009, the French drug regulatory agency (Afssaps) published the second report on its mechanism for handling the conflicts of interest of outside experts performing tasks within Afssaps. Despite the statutory requirements for experts to disclose their conflicts of interest every year, some of these experts do not. There is no procedure in place to verify their disclosure statements. In contravention of Afssaps's rules, more than half of the experts whose conflicts of interest were rated as "major" did not leave the room while a case with which they had ties was examined. Above all, expert evaluation that is free from the influence of drug companies needs to be encouraged and its value recognised.
2009年11月，法国药品监管机构（法国卫生安全和健康产品局）发布了第二份关于其处理在该局内部履行职责的外部专家利益冲突机制的报告。尽管有法定要求，专家需每年披露其利益冲突，但仍有部分专家未这样做。目前没有程序来核实他们的披露声明。违反法国卫生安全和健康产品局规定的是，超过半数利益冲突被评为“重大”的专家在审议与其有关联的案件时并未离开房间。最重要的是，需要鼓励并认可不受制药公司影响的专家评估及其价值。
